Scholarlink

Objective <p>This study aimed to elucidate the molecular mechanisms by which Apigenin (APG) reverses MET-TKI resistance in non-small cell lung cancer (NSCLC).</p> Methods <p>Network pharmacology and molecular docking were used to identify potential targets and signaling pathways of APG. Functional enrichment and protein–protein interaction analyses were integrated with in vitro validation, including CCK-8, wound healing, flow cytometry, and Western blot assays.</p> Results <p>Key hub genes such as MET, IGF1R, and PTGS2 were identified, primarily enriched in the PI3K/AKT and MAPK pathways. APG inhibited cell proliferation and migration, enhanced apoptosis, and reduced phosphorylation of MET and AKT in MET-TKI–resistant EBC-1-TepR cells.</p> Conclusion <p>This study provides systematic evidence by integrating computational approaches with experimental methods, revealing that APG can regulate multiple targets related to drug resistance and inhibit the MET/PI3K/AKT signaling pathway. This indicates that APG can reverse acquired MET-TKI resistance in non-small cell lung cancer by targeting the core recovery pathways within the tumor. It offers a novel combination strategy for adjuvant treatment to overcome MET-TKI resistance in NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative network pharmacology and in vitro validation reveal the mechanisms by which Apigenin reverses MET-TKI resistance in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月20日

查看全文
  • Xiaofei Li,
  • Jierong Yin,
  • Huijuan Zhang,
  • Xia Wang,
  • Xiao Li,
  • Yating Gao,
  • Kaining Zhang,
  • Shuying Liu,
  • Dongfeng Zhang

摘要

Objective

This study aimed to elucidate the molecular mechanisms by which Apigenin (APG) reverses MET-TKI resistance in non-small cell lung cancer (NSCLC).

Methods

Network pharmacology and molecular docking were used to identify potential targets and signaling pathways of APG. Functional enrichment and protein–protein interaction analyses were integrated with in vitro validation, including CCK-8, wound healing, flow cytometry, and Western blot assays.

Results

Key hub genes such as MET, IGF1R, and PTGS2 were identified, primarily enriched in the PI3K/AKT and MAPK pathways. APG inhibited cell proliferation and migration, enhanced apoptosis, and reduced phosphorylation of MET and AKT in MET-TKI–resistant EBC-1-TepR cells.

Conclusion

This study provides systematic evidence by integrating computational approaches with experimental methods, revealing that APG can regulate multiple targets related to drug resistance and inhibit the MET/PI3K/AKT signaling pathway. This indicates that APG can reverse acquired MET-TKI resistance in non-small cell lung cancer by targeting the core recovery pathways within the tumor. It offers a novel combination strategy for adjuvant treatment to overcome MET-TKI resistance in NSCLC.